Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 5, 2021

AbCellera’s Covid-19 antibody enters clinical trials

AbCellera has reported that antibody LY-CoV1404, developed through its partnership with Eli Lilly, entered clinical trials in subjects with mild-to-moderate Covid-19.

AbCellera has reported that antibody LY-CoV1404, developed through its partnership with Eli Lilly, entered clinical trials in subjects with mild-to-moderate Covid-19.

Lilly expanded its ongoing BLAZE-4 trials to assess LY-CoV1404 alone and along with other monoclonal antibodies.

The antibody was developed from a fully human monoclonal antibody detected in a blood sample from a convalescent Covid-19 patient 60 days after onset of symptoms.

Unlike other neutralising antibodies, LY-CoV1404 attaches a conserved region of the SARS-CoV-2 receptor-binding domain (RBD).

According to the preclinical data released by AbCellera, LY-CoV1404 attaches to a hardly mutated area of the SARS-CoV-2 spike protein and neutralised SARS-CoV-2 and all existing variants of concern.

This includes the UK (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.426 and B.1.429), and New York (B.1.526) variants.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

As LY-CoV1404 is greatly potent, it could potentially lower the quantity of antibody required for clinical dosing and could permit a subcutaneous way of administration for either Covid-19 treatment or prophylaxis, the company noted.

AbCellera scientific director Bo Barnhart said: “The ability of SARS-CoV-2 variants to negatively alter the trajectory of the pandemic emphasises the essential need for antibody therapies that can be developed in real-time to combat the virus as it evolves.

“LY-CoV1404’s powerful neutralisation of SARS-CoV-2 allows for exploration of lower clinical doses, which may support subcutaneous administration and availability of more doses to treat patients around the world.”

When the pandemic began, AbCellera developed a Covid-19 monoclonal antibody therapy, bamlanivimab. It received authorisation for emergency use from the US Food and Drug Administration (FDA).

Bamlanivimab alone and in combination with other antibodies is so far authorised for emergency/special use in over 15 countries across the globe.

Last month, the FDA revoked the emergency use authorisation granted to bamlanivimab 700mg alone for treating mild-to-moderate Covid-19 in adults and certain paediatric patients.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU